AU679908B2 - Use of interleukin-10 to suppress graft-vs.-host disease - Google Patents

Use of interleukin-10 to suppress graft-vs.-host disease

Info

Publication number
AU679908B2
AU679908B2 AU37328/93A AU3732893A AU679908B2 AU 679908 B2 AU679908 B2 AU 679908B2 AU 37328/93 A AU37328/93 A AU 37328/93A AU 3732893 A AU3732893 A AU 3732893A AU 679908 B2 AU679908 B2 AU 679908B2
Authority
AU
Australia
Prior art keywords
interleukin
host disease
suppress graft
graft
suppress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37328/93A
Other versions
AU3732893A (en
Inventor
Rosa Bacchetta
Rene De Waal Malefyt
Maria-Grazia Roncarolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU3732893A publication Critical patent/AU3732893A/en
Application granted granted Critical
Publication of AU679908B2 publication Critical patent/AU679908B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU37328/93A 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease Ceased AU679908B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84620892A 1992-03-04 1992-03-04
US846208 1992-03-04
PCT/US1993/001665 WO1993017698A1 (en) 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease

Publications (2)

Publication Number Publication Date
AU3732893A AU3732893A (en) 1993-10-05
AU679908B2 true AU679908B2 (en) 1997-07-17

Family

ID=25297256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37328/93A Ceased AU679908B2 (en) 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease

Country Status (11)

Country Link
EP (1) EP0629130A1 (en)
JP (1) JPH07504437A (en)
KR (1) KR950700079A (en)
CN (1) CN1079166A (en)
AU (1) AU679908B2 (en)
CA (1) CA2131524A1 (en)
IL (1) IL104916A0 (en)
MX (1) MX9301192A (en)
NZ (1) NZ249754A (en)
WO (1) WO1993017698A1 (en)
ZA (1) ZA931489B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (en) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル Use of a pharmaceutical composition containing an effective amount of interleukin-10, its analogs and / or agonists
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
AU5344996A (en) * 1995-03-23 1996-10-08 Governors Of Dalhousie College And University A process of prolonging organ allograft survival
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
JPH11510806A (en) * 1995-08-09 1999-09-21 シェーリング コーポレイション Combination of interleukin 10 and cyclosporin for immunosuppressive treatment
AU4385696A (en) 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
US6090413A (en) * 1996-03-25 2000-07-18 Lee; Timothy D. Process of prolonging organ allograft survival
AU6887096A (en) * 1996-09-11 1998-04-02 Patrick T. Prendergast Immune direction therapy
AU5195098A (en) * 1996-11-06 1998-05-29 Schering Corporation Renaturation and purification of viral interleukin-10 (vil-10)
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US6447765B1 (en) 1998-03-03 2002-09-10 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
JP5008810B2 (en) 2000-04-11 2012-08-22 ユニバーシティ オブ サザン カリフォルニア Method for preventing transplant rejection using TGF-β to induce inhibitory T cells
CN105106214A (en) * 2015-08-05 2015-12-02 范国煌 Novel Lck small-molecule inhibitor for inhibiting graft-versus-host disease
SG10201606949QA (en) 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405980A1 (en) * 1989-06-28 1991-01-02 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405980A1 (en) * 1989-06-28 1991-01-02 Schering Corporation Cytokine synthesis inhibitory factor, antagonists thereof, and methods of using same

Also Published As

Publication number Publication date
KR950700079A (en) 1995-01-16
MX9301192A (en) 1994-08-31
IL104916A0 (en) 1993-07-08
CA2131524A1 (en) 1993-09-16
EP0629130A1 (en) 1994-12-21
ZA931489B (en) 1993-10-28
WO1993017698A1 (en) 1993-09-16
NZ249754A (en) 1997-06-24
CN1079166A (en) 1993-12-08
AU3732893A (en) 1993-10-05
JPH07504437A (en) 1995-05-18

Similar Documents

Publication Publication Date Title
AU679908B2 (en) Use of interleukin-10 to suppress graft-vs.-host disease
AU5006993A (en) Novel attachment of polyalkylene oxides to bio-effecting substances
AU5046693A (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
AU2300092A (en) Prostaglandin e2 treatment of impotence
IL105966A0 (en) Preparation of clavulanic acid
AU4680797A (en) Preparation of substituted guanidines
AU2921192A (en) Purification of tri-alkyl compounds of group 3a metals
AU8287787A (en) Addition of calcium compounds to the carbothermic reduction of silica
AU4552585A (en) Drinking straw of telescoping portions
AU641600B1 (en) Synthesis of desflurane
AU3959393A (en) Improvements relating to the protection of corrosion-susceptible members
AU4157293A (en) Purification of propylene oxide
GB9212410D0 (en) Production of difluoromethane
AU2720388A (en) New therapeutical use of h2-receptor-blocking compounds
AU660905B2 (en) Conversion of non-ferrous sulfides
IL105321A0 (en) Preparation of cinnamic acid derivatives
AU3810193A (en) Methods of achieving antileukemia activity using 16-membered-macrolide-type compounds
AU5252793A (en) Therapeutic for gram-positive diseases of aquatic species
AU5654994A (en) Use of dinaphthalenes compounds as antiproliferative agents
AU6922994A (en) Use of acylcarnitin to treat illnesses caused by aids
AU5080393A (en) Bystander suppression of retroviral-associated neurological disease
AU644337B2 (en) Preparation of allylphosphonic acid
AU8900891A (en) Direct oxidation of propylene to propylene oxide
AU1213288A (en) Intermediates and processes for the preparation of antihypercholesterolemic tetrazole compounds
AU3632093A (en) Combinations of compounds having antiviral activity

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired